Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
세계의 암백신 시장 규모는 2024년 106억 1,000만 달러에서 2032년 204억 7,000만 달러에 이르고, 연평균 8.6%의 높은 성장률을 나타낼 것으로 예상됩니다.
암 발병률 증가와 mRNA 플랫폼과 같은 면역치료 기술의 발전에 힘입어 이 시장은 강력한 성장세를 보이고 있습니다. 가다실(HPV)과 같은 예방 백신과 네오항원 백신과 같은 치료제 후보물질이 시장의 혁신을 촉진하고 있습니다. 특히 북미와 유럽에서의 강력한 R&D 투자와 개인 맞춤형 치료에 대한 수요 증가로 인해 채택이 더욱 가속화되고 있습니다.
| 조사 범위 |
| 조사 대상년도 |
2022-2032년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2032년 |
| 검토 단위 |
금액(미화) |
| 부문별 |
유형별, 기술별, 투여경로별, 적응증별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카 |
암백신 시장은 유형별로 예방용 백신과 치료용 백신(신항원 암백신과 기타 암백신)으로 세분화됩니다. 예방용 암백신 분야는 질병 예방에 대한 인식 증가, 정부의 예방접종 프로그램, 백신 개발 기술 발전 등을 배경으로 암백신 시장을 주도할 것으로 예상되며, mRNA 플랫폼과 같은 새로운 기술은 백신의 효능을 더욱 향상시킬 가능성이 높습니다, 접근성이 용이하다는 점에서 이 분야의 성장을 가속할 가능성이 높습니다.
암백신 시장의 투여 경로 부문은 정맥 내, 근육 내, 기타 투여 경로로 구분됩니다. 근육 내(IM) 투여는 확립된 관행, 백신 투여의 높은 효능, 효과적인 면역 반응 생성으로 인해 암백신 시장을 주도할 것으로 예상됩니다. 근육 내 투여는 백신의 흡수 효율이 높고 어떤 제형에도 적합하기 때문에 예방 및 치료용 암백신에 가장 적합합니다. 또한, 임상 및 외래에서 쉽게 사용할 수 있고 의료 서비스 제공업체에게 필요한 교육이 최소화되어 집단 예방 접종 프로그램에 대한 접근성과 확장성이 향상됩니다. 따라서 이러한 모든 매개 변수는 IM 경로가 암백신 분야에서 지배적이고 실현 가능한 대안으로 자리 매김하고 있습니다.
"북미: 암백신 시장에서 가장 큰 점유율을 차지"
지역별로 보면, 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 북미는 2023년 암백신 시장을 장악할 것으로 예상되며, 시장 추정 및 예측 기간 동안에도 우위를 유지할 것으로 예측됩니다. 첨단 의료 인프라, 생명공학에 대한 높은 수준의 투자, 이 분야의 혁신을 주도하는 주요 제약사들의 강력한 입지가 시장 성장을 가속화하는 주요 요인으로 작용하고 있습니다.
이 보고서는 세계의 암백신 시장을 조사했으며, 유형별/기술별/투여 경로별/적응증별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 밸류체인 분석
- 생태계 분석
- 기술 분석
- 특허 분석
- 가격 분석
- 2024-2025년 주요 컨퍼런스 및 이벤트
- 규제 상황
- 투자와 자금조달 시나리오
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 무역 분석
- AI/생성형 AI가 암백신 시장에 미치는 영향
- 파이프라인 분석
제6장 암백신 시장(유형별)
제7장 암백신 시장(기술별)
제8장 암백신 시장(투여 경로별)
제9장 암백신 시장(적응증별)
제10장 암백신 시장(최종사용자별)
제11장 암백신 시장(지역별)
- 서론
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 기타
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동
- 아프리카
제12장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점, 2023년
- 매출 분석, 2019년-2023년
- 시장 순위, 2023년과 2032년
- 기업 평가 매트릭스 : 주요 시장 진출기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제13장 기업 개요
- 주요 시장 진출기업
- MERCK & CO., INC.
- GSK PLC.
- DENDREON PHARMACEUTICALS LLC.(SANPOWER GROUP)
- JW CREAGENE(JW SHINYAK)
- SERUM INSTITUTE OF INDIA PVT. LTD.
- VERITY PHARMACEUTICALS, INC.
- WANTAI BIOPHARM
- SHANGHAI ZERUN BIOTECH CO., LTD.(WALVAX BIOTECHNOLOGY CO., LTD.)
- VACCINOGEN
- 기타 기업(임상시험 중인 제품을 보유한 기업)
- BIONTECH
- GRITSTONE BIO
- OSE-IMMUNO
- OBI PHARMA
- SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
- MODERNA INC.
- BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
- GREENWICH LIFESCIENCES, INC.
- ASTON SCI. INC.
- TRANSGENE
- SELLAS LIFE SCIENCES GROUP INC.
제14장 부록
LSH
The global cancer vaccines market is projected to surpass USD 20.47 billion in 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%. The market is witnessing robust growth, fueled by rising cancer prevalence and advancements in immunotherapy technologies like mRNA platforms. Preventive vaccines such as Gardasil (HPV) and therapeutic candidates like neoantigen vaccines are driving innovation in the market. Strong R&D investments, especially in North America and Europe, combined with increasing demand for personalized therapies, are further accelerating adoption.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Units Considered | Value (USD) |
| Segments | By Type, Technology, Route of Administration, Indication and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The preventive cancer vaccines segment accounted for the highest share in 2023."
On the basis of type, the cancer vaccines market is further segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive cancer vaccines segment is anticipated to lead the cancer vaccines market, driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies, such as mRNA platforms, are further likely to enhance vaccine efficacy and accessibility is likely to boost the segmental growth.
"By route of administration, intramuscular segment accounted for the largest share in the cancer vaccines market."
The route of administration segment of the cancer vaccines market is segmented into intravenous, intramuscular, and other route of administration. Intramuscular (IM) route of administration is expected to lead the cancer vaccines market owing to the established practice, high efficacy of the administration of the vaccine, and creation of an effective immune response. IM administration guarantees a high efficiency of vaccine absorption and compatibility with any kind of formulation, therefore it is the most appropriate for preventive and treatment cancer vaccines. Its ease of use in clinical and outpatient settings, along with minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs. All of these parameters therefore position the IM route as the dominant and feasible option in the cancer vaccine field.
"North America: the largest share of the cancer vaccines market"
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the cancer vaccines market in 2023 and is estimated to continue dominance during the forecast period. Advanced healthcare infrastructure, high levels of investment in biotechnology, and strong presence of leading pharmaceutical companies driving innovation in the field. are some of the prominent factors accelerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cancer vaccines market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 65% and Demand Side 35%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others are some of the major players operating in the cancer vaccines market.
Research Coverage:
This research report categorizes the cancer vacciness market type (preventive and therapeutic [neoantigen cancer vaccines & other cancer vaccines]), technology (cell-based vaccines, recombinant, others), route of administration (intramuscular, intravenous, other routes of administration), indication (cervical cancer, prostrate cancer, other indications), end user (hospitals, others) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cancer vacciness market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cancer vaccines market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cancer vaccines and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing Awareness and Preventive Healthcare Measures, Rising Cancer Incidence Globally, Increased investments into R&D of Neoantigen cancer vaccines and Technological Advancements in Immunotherapy), restraints (Lengthy Clinical Trial Processes and Vaccine Hesitancy & Limited Adoption and High Development and Manufacturing Costs), opportunities (Collaborations & Strategic Partnerships and Incorporation of Artificial Intelligence (AI) & Big Data) and Challenges (Personalized Medicine & Heterogeneity of Cancer Types and Competition from Alternative Therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in cancer vaccines manufacturing, research and development activities, and new product launches in the cancer vaccines market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer vaccines market
- Competitive Assessment: Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others in the market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.2 PRIMARY DATA
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 MARKET ESTIMATION
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 TOP-DOWN APPROACH
- 2.3 MARKET GROWTH RATE PROJECTION
- 2.4 DATA TRIANGULATION
- 2.5 RESEARCH ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 CANCER VACCINES MARKET OVERVIEW
- 4.2 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
- 4.3 CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032
- 4.4 CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increased investments in neoantigen cancer vaccine R&D
- 5.2.1.2 Technological advancements in immunotherapy
- 5.2.1.3 Increasing awareness and preventive healthcare measures
- 5.2.1.4 Rising cancer incidence globally
- 5.2.2 RESTRAINTS
- 5.2.2.1 High development and manufacturing costs
- 5.2.2.2 Lengthy clinical trial processes & vaccine hesitancy and limited adoption
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Collaborations and strategic partnerships
- 5.2.3.2 Incorporation of AI and big data
- 5.2.4 CHALLENGES
- 5.2.4.1 Personalized medicine and heterogeneity of cancer types
- 5.2.4.2 Competition from alternative therapies
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.5.1 RAW MATERIAL PROVIDERS
- 5.5.2 PRODUCT PROVIDERS
- 5.5.3 END USERS
- 5.5.4 REGULATORY LANDSCAPE
- 5.6 TECHNOLOGY ANALYSIS
- 5.6.1 KEY TECHNOLOGIES
- 5.6.1.1 mRNA-based vaccines
- 5.6.1.2 Dendritic cell vaccines
- 5.6.1.3 Recombinant vector-based vaccines
- 5.6.2 COMPLEMENTARY TECHNOLOGIES
- 5.6.2.1 Artificial Intelligence (AI) and Machine Learning (ML)
- 5.6.2.2 Adjuvants for immuno-stimulation
- 5.6.3 ADJACENT TECHNOLOGIES
- 5.6.3.1 CAR T-cell therapy
- 5.6.3.2 CRISPR-based gene editing
- 5.7 PATENT ANALYSIS
- 5.7.1 METHODOLOGY
- 5.7.2 NUMBER OF PATENTS FILED
- 5.7.3 INNOVATIONS AND PATENT APPLICATIONS
- 5.8 PRICING ANALYSIS
- 5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023
- 5.8.2 AVERAGE SELLING PRICE, BY REGION, 2023
- 5.9 KEY CONFERENCES & EVENTS, 2024-2O25
- 5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10.2 REGULATORY FRAMEWORK
- 5.10.2.1 North America
- 5.10.2.2 Europe
- 5.10.2.3 Asia Pacific
- 5.11 INVESTMENT & FUNDING SCENARIO
- 5.12 PORTER'S FIVE FORCES ANALYSIS
- 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.12.2 BARGAINING POWER OF SUPPLIERS
- 5.12.3 BARGAINING POWER OF BUYERS
- 5.12.4 THREAT OF SUBSTITUTES
- 5.12.5 THREAT OF NEW ENTRANTS
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.13.1 KEY STAKEHOLDERS
- 5.13.2 KEY BUYING CRITERIA
- 5.14 TRADE ANALYSIS
- 5.14.1 IMPORT DATA FOR HS CODE 300241
- 5.14.2 EXPORT DATA FOR HS CODE 300241
- 5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET
- 5.16 PIPELINE ANALYSIS
6 CANCER VACCINES MARKET, BY TYPE
- 6.1 INTRODUCTION
- 6.2 PREVENTIVE VACCINES
- 6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH
- 6.3 THERAPEUTIC VACCINES
- 6.3.1 NEOANTIGEN CANCER VACCINES
- 6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth
- 6.3.2 OTHER THERAPEUTIC VACCINES
7 CANCER VACCINES MARKET, BY TECHNOLOGY
- 7.1 INTRODUCTION
- 7.2 CELL-BASED VACCINES
- 7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH
- 7.3 RECOMBINANT VACCINES
- 7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET
- 7.4 OTHER VACCINE TECHNOLOGIES
8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION
- 8.1 INTRODUCTION
- 8.2 INTRAMUSCULAR ROUTE
- 8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH
- 8.3 OTHER ROUTES OF ADMINISTRATION
9 CANCER VACCINES MARKET, BY INDICATION
- 9.1 INTRODUCTION
- 9.2 CERVICAL & RELATED CANCERS
- 9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH
- 9.3 OTHER INDICATIONS
10 CANCER VACCINES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 HOSPITALS
- 10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH
- 10.3 SPECIALTY CLINICS & CENTERS
- 10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET
11 CANCER VACCINES MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 ASIA PACIFIC
- 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.2.2 CHINA
- 11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
- 11.2.3 JAPAN
- 11.2.3.1 Government initiatives for vaccines to boost market
- 11.2.4 INDIA
- 11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market
- 11.2.5 SOUTH KOREA
- 11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector
- 11.2.6 REST OF ASIA PACIFIC
- 11.3 NORTH AMERICA
- 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.3.2 US
- 11.3.2.1 US to dominate North American market during forecast period
- 11.3.3 CANADA
- 11.3.3.1 Increasing government funding for vaccine research to drive market growth in Canada
- 11.4 EUROPE
- 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.4.2 GERMANY
- 11.4.2.1 Increasing investments by key players and growing funding from government organizations to drive market
- 11.4.3 UK
- 11.4.3.1 Rising investments in vaccine development to boost market growth
- 11.4.4 FRANCE
- 11.4.4.1 Support for biotechnology and research to drive market growth
- 11.4.5 ITALY
- 11.4.5.1 Government initiatives for vaccine development to boost market growth
- 11.4.6 SPAIN
- 11.4.6.1 Increasing investments in vaccine development by government and private organizations to support market growth
- 11.4.7 REST OF EUROPE
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Proactive healthcare policies to support market growth
- 11.5.3 MEXICO
- 11.5.3.1 Government commitment to immunization programs to fuel growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 11.6.2 GCC COUNTRIES
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET
- 12.3 REVENUE ANALYSIS, 2019-2023
- 12.4 MARKET RANKING, 2023 AND 2032
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 12.5.5.1 Company footprint
- 12.5.5.2 Region footprint
- 12.5.5.3 Type footprint
- 12.5.5.4 Technology footprint
- 12.5.5.5 Route of administration footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 12.7 COMPANY VALUATION & FINANCIAL METRICS
- 12.7.1 FINANCIAL METRICS
- 12.7.2 COMPANY VALUATION
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES & APPROVALS
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 MERCK & CO., INC.
- 13.1.1.1 Business overview
- 13.1.1.2 Products offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Deals
- 13.1.1.3.2 Expansions
- 13.1.1.4 MnM view
- 13.1.1.4.1 Key strengths
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 GSK PLC.
- 13.1.2.1 Business overview
- 13.1.2.2 Products offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Product approvals
- 13.1.2.4 MnM view
- 13.1.2.4.1 Key strengths
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP)
- 13.1.3.1 Business overview
- 13.1.3.2 Products offered
- 13.1.3.3 MnM view
- 13.1.3.3.1 Key strengths
- 13.1.3.3.2 Strategic choices
- 13.1.3.3.3 Weaknesses & competitive threats
- 13.1.4 JW CREAGENE (JW SHINYAK)
- 13.1.4.1 Business overview
- 13.1.4.2 Products offered
- 13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD.
- 13.1.5.1 Business overview
- 13.1.5.2 Products offered
- 13.1.5.3 Recent developments
- 13.1.5.3.1 Product launches
- 13.1.5.3.2 Deals
- 13.1.6 VERITY PHARMACEUTICALS, INC.
- 13.1.6.1 Business overview
- 13.1.6.2 Products offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Product approvals
- 13.1.7 WANTAI BIOPHARM
- 13.1.7.1 Business overview
- 13.1.7.2 Products offered
- 13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.)
- 13.1.8.1 Business overview
- 13.1.8.2 Products offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Product approvals
- 13.1.9 VACCINOGEN
- 13.1.9.1 Business overview
- 13.1.9.2 Products offered
- 13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES)
- 13.2.1 BIONTECH
- 13.2.1.1 BioNTech: Products under clinical studies
- 13.2.2 GRITSTONE BIO
- 13.2.2.1 Gritstone Bio: Products under clinical studies
- 13.2.3 OSE-IMMUNO
- 13.2.3.1 OSE-Immuno: Products under clinical studies
- 13.2.4 OBI PHARMA
- 13.2.4.1 OBI Pharma: Products under clinical studies
- 13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
- 13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies
- 13.2.6 MODERNA INC.
- 13.2.6.1 Moderna: Products under clinical studies
- 13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
- 13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies
- 13.2.8 GREENWICH LIFESCIENCES, INC.
- 13.2.8.1 Greenwich LifeSciences: Products under clinical studies
- 13.2.9 ASTON SCI. INC.
- 13.2.9.1 Aston Sci.: Products under clinical studies
- 13.2.10 TRANSGENE
- 13.2.10.1 Transgene: Products under clinical studies
- 13.2.11 SELLAS LIFE SCIENCES GROUP INC.
- 13.2.11.1 Sellas Life Sciences Group: Products under clinical studies
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
